|
Sarcoma
|
0.330 |
Biomarker
|
group |
BEFREE |
To interrogate cellular heterogeneity in mouse glioma models, we utilized a replication-competent avian sarcoma-leukosis virus long terminal repeat with splice acceptor/tumor virus A (RCAS-tva) system to generate spontaneous mouse gliomas that contained a Sox2-enhanced green fluorescent protein (EGFP) reporter.
|
25416826 |
2015 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.
|
27415467 |
2016 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
mRNA expression of transcription factors OCT3/4 and SOX2 highly correlated in primary prostate tumor tissue samples.
|
20303530 |
2010 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.
|
31358900 |
2019 |
|
Thoracic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.
|
26343384 |
2015 |
|
Neoplasms, Intracranial
|
0.300 |
Biomarker
|
group |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Intellectual Disability
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Intellectual Disability
|
0.110 |
Biomarker
|
group |
BEFREE |
No additional SOX2 loss-of-function mutations were detected in this cohort, showing that SOX2 is clearly not a major cause of intellectual disability without anophthalmia/microphthalmia.
|
27862890 |
2017 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
SOX2 mutation causes anophthalmia, hearing loss, and brain anomalies.
|
16145681 |
2005 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Germinal mosaicism and familial recurrence of a SOX2 mutation with highly variable phenotypic expression extending from AEG syndrome to absence of ocular involvement.
|
17219395 |
2007 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Supernumerary impacted teeth in a patient with SOX2 anophthalmia syndrome.
|
20803647 |
2010 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Association of anophthalmia and esophageal atresia: four new cases identified by the anophthalmia/microphthalmia clinical registry.
|
15578584 |
2005 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Status dystonicus in two patients with SOX2-anophthalmia syndrome and nonsense mutations.
|
27427475 |
2016 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
SOX2 anophthalmia syndrome.
|
15812812 |
2005 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Novel SOX2 mutations and genotype-phenotype correlation in anophthalmia and microphthalmia.
|
19921648 |
2009 |
|
Multiple congenital anomalies
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans.
|
16932809 |
2006 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to explore the prognostic role of SOX2 in a large series of squamous cell carcinomas and adenocarcinomas of the lung.
|
21460799 |
2011 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry was performed for the CSC markers Lgr5 and SOX2 and the immune-associated markers CD8, Foxp3 and PD-L1 in 79 cases of endoscopically-excised rectal lesions, ranging from low grade adenoma (LG) to invasive adenocarcinoma (AdCa).
|
30405752 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we examined a large spectrum of lung cancer entities with neuroendocrine differentiation (ie, small cell cancers, large cell cancers, typical and atypical carcinoids) for SOX2 and TTF1 copy number gains to reveal potential molecular ties to squamous cell carcinomas or adenocarcinomas of the lung.
|
21334718 |
2011 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Regulation of nestin via Akt/Sox2 is, thus, a promising candidate for novel therapeutic approaches to eradicate CSCs in lung AD.
|
24481417 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX2 amplifications were found in subsets of SCCs (37.5%), SNUCs (35.3%), INVCs (37.5%) and ADs (8.3%) but not in ACCs.
|
23544055 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, Sox2 amplification was more frequent in SCCs (52/70; 72%) than in ADCs (6/77; 8%) (P < .0001).
|
23086772 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis of overall survival indicated increased SOX2 gene copy number (P = 0.008), stage I-II (P<0.001), and adenocarcinoma or SCC histology (P = 0.016) as independent, favorable prognostic factors.
|
24736592 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas.
|
31447265 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we sought to characterize the expression profile of SOX2 and CDX2 in the sequential alterations of the esophageal mucosa towards adenocarcinoma and compare it with the well-established gastric and intestinal mucin profiles (MUC5AC, MUC6, and MUC2).
|
27766003 |
2016 |